Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Amod Sarnaik"'
Autor:
Sarah Nikiforow, John Haanen, Igor Puzanov, Rodabe Amaria, Amod Sarnaik, Marcus O Butler, Michael R Bishop, Adam J Schoenfeld, Krishna Komanduri
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Adoptive cell therapy with autologous, ex vivo-expanded, tumor-infiltrating lymphocytes (TILs) is being investigated for treatment of solid tumors and has shown robust responses in clinical trials. Based on the encouraging efficacy, tolerable safety
Externí odkaz:
https://doaj.org/article/4e07c2e8bb504c78877c9560e59a0a72
Autor:
Jessica C Hassel, James Larkin, Madan Jagasia, Harriet Kluger, Omid Hamid, Jeffrey Weber, Jason Chesney, Amod Sarnaik, John M Kirkwood, Eric Whitman, Martin Wermke, Evidio Domingo-Musibay, Theresa Medina, Sajeve Thomas, Wen Shi, Karl D Lewis, Nikhil I Khushalani, Parameswaran Hari, Marlana Orloff, Mike Cusnir, Giao Q Phan, Andrew J S Furness, Michael E Egger, Friedrich Graf Finckenstein, Giri Sulur
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Background Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assess
Externí odkaz:
https://doaj.org/article/900e2415861b4b7ead600bdf8b2b9e19
Autor:
Amy Hall, Shari Pilon-Thomas, John Mullinax, MacLean Hall, Allison Richards, Amod Sarnaik, Jamie Teer, Patrick Innamarato, Matthew Beatty, Jonathan Hensel, Holly Branthoover, Alex Alfaro, Jeani Rich, Jim Bender, Jake Ceccarelli, TJ Langer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/6bc0fb39c831449394ac7026a9dc418e
Autor:
Omid Hamid, Robert Hawkins, Paul Robbins, Gregory Daniels, Geoffrey Gibney, Amod Sarnaik, Brian Gastman, Bartosz Chmielowski, Evidio Domingo-Musibay, Sajeve Thomas, Pippa Corrie, Donald Lawrence, Yizhou Jiang, Rubén Alvarez-Rodríguez, Audrey Kennedy, Jeff Aycock, John Le Gall, Zachary Roberts
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/06069b3eb87542debd0ed796bfbea8f3
Autor:
Shari Pilon-Thomas, Daniel Abate-Daga, Amod Sarnaik, Dongliang Du, Matthew Beatty, Renata Rossetti, Leticia Tordesillas, Yian Ann Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/3d327b5a71eb4de1b0deb2a0cff28cff
Autor:
Saurabh K. Garg, Matthew J. Ott, A. G. M. Mostofa, Zhihua Chen, Y. Ann Chen, Jodi Kroeger, Biwei Cao, Adam W. Mailloux, Alisha Agrawal, Braydon J. Schaible, Amod Sarnaik, Jeffrey S. Weber, Anders E. Berglund, James J. Mulé, Joseph Markowitz
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Phenotyping of immune cell subsets in clinical trials is limited to well-defined phenotypes, due to technological limitations of reporting flow cytometry multi-dimensional phenotyping data. We developed a multi-dimensional phenotyping analysis tool a
Externí odkaz:
https://doaj.org/article/27868eabfece4beba9ed09c42344dbf3
Autor:
Daniel E Oliver, Vernon K Sondak, Tobin Strom, Jonathan S Zager, Arash O Naghavi, Amod Sarnaik, Jane L Messina, Jimmy J Caudell, Andy M Trotti, Javier F Torres-Roca, Nikhil I Khushalani, Louis B Harrison
Publikováno v:
Melanoma Management, Vol 5, Iss 1 (2018)
Aim: We assessed the role of adjuvant interferon on relapse-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS) in node-positive melanoma patients. Methods: We retrospectively reviewed 385 node-positive patients wit
Externí odkaz:
https://doaj.org/article/d4e2fb09187f4fb8b62c00e2a01df5fa
Autor:
Jessica Ann Chacon, Richard C Wu, Pariya Sukhumalchandra, Jeffrey J Molldrem, Amod Sarnaik, Shari Pilon-Thomas, Jeffrey Weber, Patrick Hwu, Laszlo Radvanyi
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e60031 (2013)
Adoptive T-cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) can induce tumor regression in up to 50% or more of patients with unresectable metastatic melanoma. However, current methods to expand melanoma TIL, especially the "rapid expans
Externí odkaz:
https://doaj.org/article/2124e052c95e440183d0f04d26b2e603
Autor:
Jeffrey Weber, Eduardo M. Sotomayor, Amod Sarnaik, Alejandro Villagra, Andressa L. Sodré, David M. Woods
Supplemental Figure 1. HDAC inhibition upregulates PD-L1 in a melanoma cell line in a dose dependent manner. Supplemental Figure 2. DNA methyltransferase (DNMT) inhibitors increase PD-L1 and PD-L2 expression in melanoma. Supplemental Figure 3. Verifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cafa4c6f093a19630308a493201432e9
https://doi.org/10.1158/2326-6066.22538872
https://doi.org/10.1158/2326-6066.22538872
Autor:
Jeffrey Weber, Eduardo M. Sotomayor, Amod Sarnaik, Alejandro Villagra, Andressa L. Sodré, David M. Woods
Expression of PD-1 ligands by tumors and interaction with PD-1–expressing T cells in the tumor microenvironment can result in tolerance. Therapies targeting this coinhibitory axis have proven clinically successful in the treatment of metastatic mel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::084b2db18d57eba1c0aabbda04874e26
https://doi.org/10.1158/2326-6066.c.6548923.v1
https://doi.org/10.1158/2326-6066.c.6548923.v1